Coloplast A/S - Opdateret finanskalender 2025-26 Venligst se vedlagte pdf. Opdatering af datoer i finanskalenderen Coloplast har opdateret datoerne i selskabets finanskalender vedrørende offentliggørelsen af årsregnskabet for 2025/26 samt afholdelsen af den ordinære generalforsamling 2026. De opdaterede datoer er som følger: Årsregnskabsmeddelelse for 2025/26 og Årsrapport 2025/26: ændret fra 5. november 2026 til 3. november 2026Ordinær generalforsamling 2026: ændret fra 3. december 2026 til 1. december 2026 For yderligere information og kalenderinvitationer til kommende beg...
Coloplast A/S - Updated Financial Calendar 2025-26 Please see enclosed pdf. Update to Financial Calendar Dates Coloplast has updated the dates in its financial calendar for the publication of the FY Financial Statements 2025/26 and the Annual General Meeting 2026. The updated dates are as follows: Financial Statements for the full year 2025/26 and Annual Report 2025/26: changed from November 5, 2026 to November 3, 2026Annual General Meeting 2026: changed from December 3, 2026 to December 1, 2026 For more information and calendar invitations for upcoming events, please visit: Kind...
A director at Sonova Holding AG bought 500 shares at 204.355CHF and the significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Coloplast A/S - Regnskabsmeddelelse, Q1 2025/26 2025/26 Delårsrapport, 1. kvartal 2025/261. oktober 2025 - 31. december 2026 Coloplast leverede i 1. kvartal en organisk vækst på 6% og en EBIT vækst1 i faste valutakurser på 3%. Den rapportede omsætning i danske kroner steg 0%, hvilket afspejler en negativ valutaeffekt på 4 procentpoint. Afkast af investeret kapital2 var på 15%. • Organisk vækst pr. område: Stomi 4 %, Kontinens 7 %, Stemme og Respiratorisk Pleje 8 %, Wound & Tissue Repair 5 % og Urologi 8 %.• Svag start i Stomi, som forventet, drevet af negativ vækst i Kina og høj baseli...
Coloplast A/S - Interim Financial Report, Q1 2025/26 2025/26Interim financial results, Q1 2025/261 October 2025 - 31 December 2025 Coloplast delivered Q1 organic growth of 6% and EBIT growth1 in constant currencies of 3%. Reported revenue in DKK grew 0%, reflecting 4%-points negative impact from currencies. Return on invested capital2 was 15%. • Organic growth rates by business area: Ostomy Care 4%, Continence Care 7%, Voice & Respiratory Care 8%, Wound & Tissue Repair 5%, and Interventional Urology 8% .• Soft start in Ostomy Care, as expected, driven by negative growth in China and a high...
Coloplast A/S - Q1 2025/26 Earnings Release - Invitation for conference call on 6 Feb 2026 at 11.00am CET Friday, 6 February 2026 at 11:00-12:00am CETIn connection with the publication of Coloplast’s interim financial results for Q1 2025/26, to be released same day around 07.30am CET, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.The webcast of the conference call will be available during and after the e...
La saison de résultats ne devrait pas apporter de mauvaises surprises concernant la fin 2025 (cf. messages rassurants lors de nos conférences et des pre-close calls) mais les perspectives 2026 devraient rester prudentes face au manque de visibilité. Face à cela, les managements vont à nouveau concentrer leurs efforts sur les leviers internes et l’agilité mais le sentiment sur le secteur pourrait rester fragile à court terme, nous conduisant à maintenir nos estimations prudentes et une approche o...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.